As Senior Vice President, Business & Consumer Markets, Lawrence is responsible for driving revenue and profitability within LifeLabs’ B2B and B2C portfolio, managing the consumer product life cycle, marketing, and commercial partnership activities across consumer and B2B segments.
Lawrence has extensive experience in the healthcare industry, having worked in European and North American markets in both the medical device and healthcare services sectors. Before joining LifeLabs in November 2017, Lawrence led the diagnostic system business at BD (Becton Dickinson) Canada, where his teams were recognized with global achievement awards on three separate occasions.
Lawrence has held a number of commercial leadership roles throughout his career, including biotechnology trading for the Czechoslovakian trading agency, Chemapol (UK), and business development throughout Western Europe for CellPro Inc. — a pioneer of stem cell-based therapy. Lawrence has expertise in sales and marketing operations, performance management, strategic marketing and growth strategy.
Since joining LifeLabs, Lawrence has led several robust initiatives across multiple levels of the organization, from spearheading developments during the early days of the organization’s MyVisit™ mobile service program to launching innovative solutions during the COVID-19 pandemic such as FlyClear™. In addition, he has developed valuable partnerships with companies such as Sun Life and Bayer Inc., to launch products such as the FastTRK for TRK fusion cancer patients, as well as Klinrisk to advance chronic kidney disease management. Furthermore, Lawrence’s commitment to enhancing the overall patient experience has introduced more convenient and flexible solutions for the modern customer with the launch of LifeLabs’ At Home Kit program that offers an array of at-home sample collection kits for essential testing services.
Lawrence holds a Bachelor of Science degree in Biochemistry from University College Cardiff and is a board member of the Inscyte Corporation, a not-for-profit health data technology company. In 2024, he was recognized among the Top 25 Executives in Biotechnology by The Healthcare Technology Report, which selects candidates who have demonstrated ingenuity, skill, and perseverance in solving tremendous challenges in the realm of healthcare, medicine, and biotechnology field.